Prolor Biotech receives allowance for patent application

Monday, July 11, 2011 12:43 PM

Prolor Biotech has received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for a patent application covering the company’s CTP platform, which has the potential to extend the duration of activity of virtually all therapeutic proteins. The allowed claims cover CTP-modified compositions of a wide array of classes of therapeutic proteins, including hormones, high affinity protein ligands, proteins that induce or regulate an immune response, proteins that are involved with autocrine and paracrine activities and mimetics of these therapeutic proteins, as well as other types of proteins.

“Allowance of this new patent is of great importance for PROLOR’s intellectual property portfolio, since it covers a very wide array of therapeutic proteins and extends the patent protection around our CTP platform for many years," said Shai Novik, president of Prolor. 

This new U.S. patent is expected to issue in the next few months.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs